期刊文献+

表没食子儿茶素没食子酸酯抗感染特性研究进展 被引量:4

Progress of researches on anti-infective properties of epigallocatechin-3-gallate
原文传递
导出
摘要 表没食子儿茶素没食子酸酯[(-)-epigallocatechin-3-O-gallate, EGCG]是绿茶中含量最丰富的多酚类化合物,具有抗氧化、抗炎、抗血栓、抗辐射、抗突变、抗肿瘤、抗纤维化等广泛生物学功能,对糖尿病、肥胖、哮喘、癌症、心血管系统和神经系统疾病等有一定改善和治疗作用,亦可提高机体免疫力。近年来研究发现,EGCG在细菌、真菌、病毒、寄生虫等病原微生物引起的感染性疾病中发挥重要作用。本文就EGCG抗感染特性研究进展进行综述,以揭示其在预防和治疗感染性疾病中的潜在作用。 (-)-epigallocatechin-3-O-gallate(EGCG) is the most abundant polyphenol in green tea, which has shown antioxidant, anti-inflammatory, anti-thrombotic, anti-radiation, anti-mutant, anti-cancer and anti-fibrotic actions, and has shown improvements of diabetes, obesity, asthma, cancer, cardiovascular diseases and central nervous system disorders. In addition,EGCG is reported to enhance the human immunity. Recently, EGCG has been found to play a vital role in infectious diseases caused by pathogenic microorganisms, including bacteria, fungi, viruses and parasites. The review summarizes the progress of researches on anti-infective properties of EGCG, so as to elucidate the potential role of EGCG in the prevention and treatment of infectious diseases.
作者 杜伟勤 薛婷 DU Wei-qin;XUE Ting(Department of Medical Laboratory,the 11th Clinical Medical College,Shanxi Medical University,Lüliang,Shanxi 033000,Chi-na;National Health Commission Key Laboratory of Pneumoconiosis,Department of Respiratory and Critical Medicine,the First Hospital of Shanxi Medical University,Taiyuan,Shanxi 030001,China)
出处 《中国血吸虫病防治杂志》 CAS CSCD 北大核心 2022年第1期102-108,共7页 Chinese Journal of Schistosomiasis Control
基金 山西省自然科学基金基础研究计划项目(20210302124039) 山西省高等学校科技创新项目(2020L0201,2020L0223) 山西医科大学省级博士基金项目(SD1905) 山西医科大学校级博士启动基金项目(XD1905)。
关键词 表没食子儿茶素没食子酸酯 抗感染效果 药理作用 (-)-epigallocatechin-3-O-gallate Anti-infective activity Pharmacological action
  • 相关文献

参考文献3

二级参考文献33

  • 1Canrong Wu,Yang Liu,Yueying Yang,Peng Zhang,Wu Zhong,Yali Wang,Qiqi Wang,Yang Xu,Mingxue Li,Xingzhou Li,Mengzhu Zheng,Lixia Chen,Hua Li.Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods[J].Acta Pharmaceutica Sinica B,2020,10(5):766-788. 被引量:75
  • 2Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000; 342: 232-9. 被引量:1
  • 3Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox N J, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292: 1333-40. 被引量:1
  • 4Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, et al. Pandemic potential of a strain of influenza A (HIN1): early findings. Science 2009; 324: 1557-61. 被引量:1
  • 5Scalera NM, Mossad SB. The first pandemic of the 21st century: a review of the 2009 pandemic variant influenza A (HIN1) virus. Post~rad Med 2009; 121: 43-7. 被引量:1
  • 6Goodman AG, Heinen PP, Guerra S, Vijayan A, Sorzano CO, Gomez CE, et al. A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus. PLoS One 2011; 6: e25938. 被引量:1
  • 7Couch RB. Prevention and treatment of influenza. N Engl J Med 2000; 343: 1778-87. 被引量:1
  • 8Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353: 1363-73. 被引量:1
  • 9Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten R J, Xu X, Bright RA, et al. Surveillance for neuraminidase inhibitor resistance amonghuman influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52: 3284-92. 被引量:1
  • 10Dharan N J, Gubareva LV, Meyer J J, Okomo-Adhiambo M, McClinton RC, Marshall SA, et al. Infections with oseltamivir-resistant influenza A(HIN1) virus in the United States. JAMA 2009; 301: 1034-41. 被引量:1

共引文献50

同被引文献61

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部